Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?
about
Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis unitsIsolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis unitsManagement of chronic hepatitis C virus infection in patients with end-stage renal disease: a reviewFatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIVYounger black patients have a higher risk of infection mortality that is mostly non-dialysis related: A national study of cause-specific mortality among U.S. maintenance dialysis patients.Hepatitis C virus infection and dialysis: 2012 update.Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens.Management of hepatitis C in patients with chronic kidney disease.Hepatitis C and kidney disease: An overview and approach to management.Hepatitis C in hemodialysis patientsA systematic review of the impact of center volume in dialysis.Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.A Cross-sectional Study of the Association Between Chronic Hepatitis C Virus Infection and Subclinical Coronary Atherosclerosis Among Participants in the Multicenter AIDS Cohort StudyUse of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.Early Results of Pilot Study Using Hepatitis C Virus (HCV) Positive Kidneys to Transplant HCV Infected Patients with End-Stage Renal Disease Allowing for Successful Interferon-Free Direct Acting Antiviral Therapy after Transplantation.Hepatitis C virus infection in end-stage renal disease and kidney transplantation.Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies.Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis.Pegylated Interferon Mono-Therapy of Chronic Hepatitis C in the Dialysis Population: Systematic Review and Meta-Analysis.What does the pharmacological future of treating chronic hepatitis C look like?Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?HCV and the kidney.Chronic hepatitis C virus infection, a new cardiovascular risk factor?The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation.Hepatitis C Virus Infection in Chronic Kidney Disease.Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment.Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease.Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series.Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease.Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.An update on the management of hepatitis C virus-infected patients with stage 4-5 chronic kidney disease while awaiting the revised KDIGO Guidelines.Chronic kidney disease: Treatment of hepatitis C virus infection in patients with CKD.Single nucleotide polymorphisms near IL28B gene and response to treatment of chronic hepatitis C in hemodialysis patients.Genetic diversity of hepatitis C virus quasispecies in chronic renal failure patients in Midwest Brazil.Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4-5 chronic kidney disease.Direct-Acting Antiviral Agents for the Hepatitis C Virus-Infected Chronic Kidney Disease Population: The Dawn of a New Era.Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney.Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review.Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers.
P2860
Q24243600-2EE34239-DC5F-4980-B828-F9AEF05178F9Q26470464-0FFF0038-D440-4450-B42E-4E920D574B2CQ26821786-B46E389B-1769-4C71-B248-FE65BACAE862Q28079826-D5DEB2AE-7009-4028-9B5D-BF35F9232875Q30276101-3B477BDE-DCCC-4A49-8388-F4C059D895D0Q33710828-0EC891AE-5F35-420D-9BB3-3E3AC73E4539Q33845581-B9EE993D-8359-4994-8FAB-18318988A5ADQ34932338-1EAAB4DA-FED4-4C9C-91C0-6FC1BF1906A8Q34966853-D2A8B6EE-36C6-4D05-948A-CF73763A4CB1Q35237329-4383B33B-3EA2-4728-B5F9-877F4B753F08Q35875944-1E7870A6-FE0B-4448-93C3-91DA180E7E51Q36220536-F38CD30C-BA70-4DD8-B524-5512B49F0E5CQ36401521-4B789D6F-A06D-445F-8043-F7AE7C6DCDB4Q36518540-D6849D6A-7043-48B8-B102-C469F176C58FQ37527974-90E76309-A079-4A5B-B06A-92F54D0ADD09Q38213956-7ADF1751-F4CE-40F2-8B11-60E7CD81D9ECQ38231457-3B3BDDD4-FC43-431B-8A3E-F798582D6EF5Q38551250-653760F1-F321-4217-8745-DBA685A7C6D4Q38551615-CB89EC04-6166-42AE-86D5-19F464540409Q38569681-32249FED-190F-41C0-A340-420CDA77AAEDQ38586088-261F6AF5-6D28-4ECE-B0B7-6F0D7447A356Q38685571-A465D6EF-FC29-4A51-AC2C-9BC33686BED8Q38695606-7CF59631-DC42-414D-8242-98CE38BD3007Q38757351-14FF6DDD-3398-4836-925C-CE960A5C95D6Q38812607-FCF43144-00E8-4512-83F9-2AE01D7A5C28Q39067369-1233391B-958D-42C5-84DB-E99E672AA135Q39102936-8E1DB320-E5BE-47E3-BDE9-24FDBE12CC9AQ39455853-DBB56189-30A9-4934-AA66-402F23318525Q40043601-D8D87D06-C5A7-4336-A1AB-640676170E3DQ40277831-E621B820-7F3B-451A-A2E4-ECB5AF893804Q40278746-5B3E6D44-7A75-488A-98D6-6ADAA26FF4A9Q40744451-F09E9DAC-2071-4C53-A16A-370EB248ABACQ40900678-142455B5-114D-46E7-97B5-7927FA8E39C9Q41601725-E3997AB7-72AF-488E-BDE2-386D58DC0FD4Q42235615-59A0DFF4-156C-4E29-973E-2F09612118FBQ42370354-04708BE9-593A-4D10-ABA4-137784218ECEQ43969652-003C0820-7EA1-4EEF-AB80-D75D66651A37Q45325791-CE016BB5-BFA6-4EF2-8C68-5843FAD31CD2Q47169604-BD6C64FB-497C-4608-AE26-6ABA9E279956Q47554287-16B5224D-3883-4BE1-956D-DF807B45C569
P2860
Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Impact of hepatitis C on survi ...... with cardiovascular mortality?
@en
type
label
Impact of hepatitis C on survi ...... with cardiovascular mortality?
@en
prefLabel
Impact of hepatitis C on survi ...... with cardiovascular mortality?
@en
P2093
P2860
P1476
Impact of hepatitis C on survi ...... with cardiovascular mortality?
@en
P2093
P2860
P304
P356
10.1111/J.1365-2893.2012.01633.X
P577
2012-07-17T00:00:00Z